Patrick Baeuerle - 17 Feb 2023 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Scientific Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
17 Feb 2023
Net transactions value
$0
Form type
4
Filing time
21 Feb 2023, 17:53:33 UTC
Previous filing
15 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $0 +38,500 +103% $0.000000 76,000 17 Feb 2023 Direct F1
holding CGEM Common Stock 341,434 17 Feb 2023 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +77,000 $0.000000 77,000 17 Feb 2023 Common Stock 77,000 $11.34 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
F2 Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F3 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Remarks:

Exhibit 24.1 - Power of Attorney